Inbiogen KRX:101140KOSPI
인바이오젠 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Inbiogen reported revenue of ₩1.5bn, down 18.4% year on year, and an operating loss of ₩924m. Inbiogen (인바이오젠) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals 4 quarters of losses Screener
Inbiogen quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1.5bn | -18.4% | −₩924m margin −61.2% | −₩1.5bn |
| Q1 2026 | ₩786m | -52.0% | −₩980m margin −124.6% | −₩14.7bn |
| Q4 2025 derived | ₩661m | -69.5% | −₩953m margin −144.3% | −₩12.7bn |
| Q3 2025 | ₩2.1bn | +3.2% | −₩1.1bn margin −49.1% | ₩8.2bn |
| Q2 2025 | ₩1.8bn | +29.9% | −₩1.0bn margin −54.3% | ₩1.1bn |
| Q1 2025 | ₩1.6bn | +19.8% | −₩1.3bn margin −80.6% | ₩2.0bn |
| Q4 2024 derived | ₩2.2bn | +38.8% | −₩2.1bn margin −97.6% | ₩14.8bn |
| Q3 2024 | ₩2.1bn | +84.5% | −₩1.3bn margin −61.7% | −₩4.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Inbiogen top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Inbiogen news Korean headlines
No articles yet.